Where does Theriva Biologics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Theriva Biologics, Inc. ranks #25,400 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Theriva Biologics, Inc. hold?

Theriva Biologics, Inc. holds 11 US utility patents granted between 2023 and 2025, spanning 6 technology areas.

What is Theriva Biologics, Inc.'s Innovation Score?

Theriva Biologics, Inc. has an Innovation Score of 45.7 out of 100 (top 23% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Theriva Biologics, Inc. focus on?

Theriva Biologics, Inc.'s top technology area is C12Y (Enzymes) with 11 patents, ranking #239 of 1,675 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Theriva Biologics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Theriva Biologics, Inc..

What does claim depth mean for Theriva Biologics, Inc.'s patents?

Theriva Biologics, Inc.'s patents average 14.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Theriva Biologics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Theriva Biologics, Inc.

USPTO PatentsView assignee record - 11 granted patents across 6 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Y (Enzymes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Theriva ranks #25,400 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 6 technology areas.

#25,400
of 49,997 US assignees by volume: Top 23%
by Innovation Score (45.7/100): 14.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R25400 · US Corporation #25,400 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 11 grants
MID-PACK #25,400/49,997
PHOTO-FINISH The Swatch Group…
CPC-NARROW C12Y · 6 areas
INNOV-PAR 45.7/100
CLAIMS-RICH 14.1 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2023–2025 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: The Swatch Group Management Services AG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Theriva’s 45.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (19%) Velocity 20.0 pts (44%) Breadth 8.7 pts (19%) Claim depth 8.5 pts (19%)

Qualcomm Incorporated · highest

85
Theriva Biologics · this assignee

46
3D Lighting… · lowest

7

What this shows Theriva's Innovation Score is 45.7/100 (top 23% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Theriva?

Each dot is one of Theriva’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Theriva’s own 14.1 claims/patent is at or below the 14.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Theriva vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Theriva's grants concentrate

Theriva Biologics, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C12Y (Enzymes). Peak complete grant year is 2024 (6 grants) versus a trough of 3 in 2023. By volume, Theriva sits between The Swatch Group Management Services AG and ThreatSTOP, Inc..

Theriva's three-year grant acceleration

Theriva Biologics, Inc. shows 9 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

The Swatch Group…

11
The University of…

11
Theracell

11
Theravance Respir…

11
Thermo Fisher Sci…

11
Thetis Phamaceuti…

11
Thread Wallets

11
Threatstop

11
Theriva Biologics ◀

11

What this shows Theriva holds 11 patents at rank #25,401, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Theriva

By rank, the assignees closest to #25,401 in granted patent volume.

Leaders in C12Y (Enzymes)

Other assignees with the most granted patents in Theriva's primary technology class.

Theriva's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 23% higher than 77% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table

Theriva Biologics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2023	3	27.3%
2024	6	54.5%
2025partial year	2	18.2%

Which technologies does Theriva Biologics, Inc. patent most?

C12Y - Enzymes 11

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 10

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

Y02A - Technologies FOR Adaptation TO Climate Change 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Theriva Biologics, Inc.'s patent record in context - here's where to go next.

Theriva Biologics, Inc.'s lead technology class is C12Y (Enzymes), 100% of its portfolio - see every assignee active in that class. Explore C12Y
Ranked #25,400 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Theriva Biologics, Inc. against The Swatch Group Management Services AG, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.